| Molecular alteration . | Histopathologic diagnosis, No. . | ||
|---|---|---|---|
| High-grade malignant neoplasms: HGDTC/PDTC (n = 7) . | Well-differentiated malignant neoplasms: FCA/OCA/PTC (n = 20) . | Benign neoplasms: FA/OA (n = 5) . | |
| TERT only (n = 4) | 0 | 3 | 1 |
| TERT + 1 additional molecular alteration (n = 17) | 2 (1 CNV, 1 GE) | 11 (3 NRAS, 2 EIF1AX, 1 BRAF V600E, 1 BRAF 1485-T488del, 1 PTEN, 1 HRAS, 1 TRA2A/THADA, 1 EZH1) | 4 (2 CNV, 1 HRAS, 1 EIF1AX) |
| TERT + 2 additional molecular alterations (n = 6) | 1 (1 NRAS + GE) | 5 (2 BRAF V600E + GE, 1 NRAS + CNV, 1 EIF1AX + HRAS, 1 HRAS + GE) | 0 |
| TERT + 3 additional molecular alterations (n = 5) | 4 (2 HRAS + CNV + GE, 1 BRAF V600E + CNV + GE, 1 NRAS + CNV + TP53) | 1 (1 BRAF V600E + GE + PIK3CA) | 0 |
| Molecular alteration . | Histopathologic diagnosis, No. . | ||
|---|---|---|---|
| High-grade malignant neoplasms: HGDTC/PDTC (n = 7) . | Well-differentiated malignant neoplasms: FCA/OCA/PTC (n = 20) . | Benign neoplasms: FA/OA (n = 5) . | |
| TERT only (n = 4) | 0 | 3 | 1 |
| TERT + 1 additional molecular alteration (n = 17) | 2 (1 CNV, 1 GE) | 11 (3 NRAS, 2 EIF1AX, 1 BRAF V600E, 1 BRAF 1485-T488del, 1 PTEN, 1 HRAS, 1 TRA2A/THADA, 1 EZH1) | 4 (2 CNV, 1 HRAS, 1 EIF1AX) |
| TERT + 2 additional molecular alterations (n = 6) | 1 (1 NRAS + GE) | 5 (2 BRAF V600E + GE, 1 NRAS + CNV, 1 EIF1AX + HRAS, 1 HRAS + GE) | 0 |
| TERT + 3 additional molecular alterations (n = 5) | 4 (2 HRAS + CNV + GE, 1 BRAF V600E + CNV + GE, 1 NRAS + CNV + TP53) | 1 (1 BRAF V600E + GE + PIK3CA) | 0 |
CNV, copy number variation; FA, follicular adenoma; FCA, follicular carcinoma; GE, gene expression profile; HGDTC, high-grade differentiated thyroid carcinoma; OA, oncocytic adenoma; OCA, oncocytic carcinoma; PDTC, poorly differentiated thyroid carcinoma; PTC, papillary thyroid carcinoma.
| Molecular alteration . | Histopathologic diagnosis, No. . | ||
|---|---|---|---|
| High-grade malignant neoplasms: HGDTC/PDTC (n = 7) . | Well-differentiated malignant neoplasms: FCA/OCA/PTC (n = 20) . | Benign neoplasms: FA/OA (n = 5) . | |
| TERT only (n = 4) | 0 | 3 | 1 |
| TERT + 1 additional molecular alteration (n = 17) | 2 (1 CNV, 1 GE) | 11 (3 NRAS, 2 EIF1AX, 1 BRAF V600E, 1 BRAF 1485-T488del, 1 PTEN, 1 HRAS, 1 TRA2A/THADA, 1 EZH1) | 4 (2 CNV, 1 HRAS, 1 EIF1AX) |
| TERT + 2 additional molecular alterations (n = 6) | 1 (1 NRAS + GE) | 5 (2 BRAF V600E + GE, 1 NRAS + CNV, 1 EIF1AX + HRAS, 1 HRAS + GE) | 0 |
| TERT + 3 additional molecular alterations (n = 5) | 4 (2 HRAS + CNV + GE, 1 BRAF V600E + CNV + GE, 1 NRAS + CNV + TP53) | 1 (1 BRAF V600E + GE + PIK3CA) | 0 |
| Molecular alteration . | Histopathologic diagnosis, No. . | ||
|---|---|---|---|
| High-grade malignant neoplasms: HGDTC/PDTC (n = 7) . | Well-differentiated malignant neoplasms: FCA/OCA/PTC (n = 20) . | Benign neoplasms: FA/OA (n = 5) . | |
| TERT only (n = 4) | 0 | 3 | 1 |
| TERT + 1 additional molecular alteration (n = 17) | 2 (1 CNV, 1 GE) | 11 (3 NRAS, 2 EIF1AX, 1 BRAF V600E, 1 BRAF 1485-T488del, 1 PTEN, 1 HRAS, 1 TRA2A/THADA, 1 EZH1) | 4 (2 CNV, 1 HRAS, 1 EIF1AX) |
| TERT + 2 additional molecular alterations (n = 6) | 1 (1 NRAS + GE) | 5 (2 BRAF V600E + GE, 1 NRAS + CNV, 1 EIF1AX + HRAS, 1 HRAS + GE) | 0 |
| TERT + 3 additional molecular alterations (n = 5) | 4 (2 HRAS + CNV + GE, 1 BRAF V600E + CNV + GE, 1 NRAS + CNV + TP53) | 1 (1 BRAF V600E + GE + PIK3CA) | 0 |
CNV, copy number variation; FA, follicular adenoma; FCA, follicular carcinoma; GE, gene expression profile; HGDTC, high-grade differentiated thyroid carcinoma; OA, oncocytic adenoma; OCA, oncocytic carcinoma; PDTC, poorly differentiated thyroid carcinoma; PTC, papillary thyroid carcinoma.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
